25 XP   0   0   10

Sprint Bioscience AB
Buy, Hold or Sell?

Let's analyse Sprint Bioscience AB together

PenkeI guess you are interested in Sprint Bioscience AB. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Sprint Bioscience AB. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Sprint Bioscience AB

I send you an email if I find something interesting about Sprint Bioscience AB.

Quick analysis of Sprint Bioscience AB (30 sec.)










What can you expect buying and holding a share of Sprint Bioscience AB? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr0.40
Expected worth in 1 year
kr0.39
How sure are you?
42.5%

+ What do you gain per year?

Total Gains per Share
kr-0.01
Return On Investment
-0.4%

For what price can you sell your share?

Current Price per Share
kr1.35
Expected price per share
kr0.83 - kr2
How sure are you?
50%

1. Valuation of Sprint Bioscience AB (5 min.)




Live pricePrice per Share (EOD)

kr1.35

Intrinsic Value Per Share

kr-3.52 - kr-0.19

Total Value Per Share

kr-3.13 - kr0.21

2. Growth of Sprint Bioscience AB (5 min.)




Is Sprint Bioscience AB growing?

Current yearPrevious yearGrowGrow %
How rich?$2.5m$3.3m-$1.5m-83.2%

How much money is Sprint Bioscience AB making?

Current yearPrevious yearGrowGrow %
Making money-$9.6k-$1.3m$1.3m14,099.3%
Net Profit Margin-7,145.9%-123,794.1%--

How much money comes from the company's main activities?

3. Financial Health of Sprint Bioscience AB (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#799 / 1010

Most Revenue
#488 / 1010

Most Profit
#166 / 1010

Most Efficient
#925 / 1010

What can you expect buying and holding a share of Sprint Bioscience AB? (5 min.)

Welcome investor! Sprint Bioscience AB's management wants to use your money to grow the business. In return you get a share of Sprint Bioscience AB.

What can you expect buying and holding a share of Sprint Bioscience AB?

First you should know what it really means to hold a share of Sprint Bioscience AB. And how you can make/lose money.

Speculation

The Price per Share of Sprint Bioscience AB is kr1.346. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Sprint Bioscience AB.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Sprint Bioscience AB, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr0.40. Based on the TTM, the Book Value Change Per Share is kr0.00 per quarter. Based on the YOY, the Book Value Change Per Share is kr-0.12 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Sprint Bioscience AB.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.01-0.5%0.000.0%-0.02-1.5%-0.01-0.7%-0.01-0.5%
Usd Book Value Change Per Share-0.01-0.5%0.000.0%-0.01-0.8%0.000.0%0.000.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.01-0.5%0.000.0%-0.01-0.8%0.000.0%0.000.1%
Usd Price Per Share0.16-0.11-0.20-0.59-1.38-
Price to Earnings Ratio-6.01--1.61--2.45--5.82-33.81-
Price-to-Total Gains Ratio-24.02--6.44--15.27--2.06-212.20-
Price to Book Ratio4.36-5.12-3.66-27.47-63.94-
Price-to-Total Gains Ratio-24.02--6.44--15.27--2.06-212.20-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.1236974
Number of shares8084
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (8084 shares)-1.10-5.04
Gains per Year (8084 shares)-4.41-20.15
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-4-140-20-30
20-9-180-40-50
30-13-220-60-70
40-18-260-81-90
50-22-300-101-110
60-26-340-121-130
70-31-380-141-150
80-35-420-161-170
90-40-460-181-190
100-44-500-202-210

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%9.031.00.022.5%9.033.00.021.4%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%7.013.00.035.0%17.022.01.042.5%18.022.02.042.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.042.00.0%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%7.013.00.035.0%17.022.01.042.5%18.022.02.042.9%

Fundamentals of Sprint Bioscience AB

About Sprint Bioscience AB

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. It develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism, nash, and diabetes. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden.

Fundamental data was last updated by Penke on 2024-04-25 06:55:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Sprint Bioscience AB.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Sprint Bioscience AB earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Sprint Bioscience AB to the Biotechnology industry mean.
  • A Net Profit Margin of -46.4% means that kr-0.46 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Sprint Bioscience AB:

  • The MRQ is -46.4%. The company is making a huge loss. -2
  • The TTM is -7,145.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-46.4%TTM-7,145.9%+7,099.6%
TTM-7,145.9%YOY-123,794.1%+116,648.1%
TTM-7,145.9%5Y-28,348.2%+21,202.3%
5Y-28,348.2%10Y-14,553.2%-13,795.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-46.4%-207.2%+160.8%
TTM-7,145.9%-216.8%-6,929.1%
YOY-123,794.1%-282.3%-123,511.8%
5Y-28,348.2%-436.8%-27,911.4%
10Y-14,553.2%-597.3%-13,955.9%
1.1.2. Return on Assets

Shows how efficient Sprint Bioscience AB is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Sprint Bioscience AB to the Biotechnology industry mean.
  • -8.1% Return on Assets means that Sprint Bioscience AB generated kr-0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Sprint Bioscience AB:

  • The MRQ is -8.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -12.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.1%TTM-12.5%+4.4%
TTM-12.5%YOY-34.1%+21.6%
TTM-12.5%5Y-26.7%+14.1%
5Y-26.7%10Y-18.9%-7.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.1%-13.3%+5.2%
TTM-12.5%-12.8%+0.3%
YOY-34.1%-11.6%-22.5%
5Y-26.7%-13.8%-12.9%
10Y-18.9%-15.6%-3.3%
1.1.3. Return on Equity

Shows how efficient Sprint Bioscience AB is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Sprint Bioscience AB to the Biotechnology industry mean.
  • -18.2% Return on Equity means Sprint Bioscience AB generated kr-0.18 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Sprint Bioscience AB:

  • The MRQ is -18.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -71.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-18.2%TTM-71.9%+53.7%
TTM-71.9%YOY-43.8%-28.0%
TTM-71.9%5Y-85.2%+13.4%
5Y-85.2%10Y-53.7%-31.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-18.2%-16.9%-1.3%
TTM-71.9%-16.1%-55.8%
YOY-43.8%-14.9%-28.9%
5Y-85.2%-19.3%-65.9%
10Y-53.7%-20.1%-33.6%

1.2. Operating Efficiency of Sprint Bioscience AB.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Sprint Bioscience AB is operating .

  • Measures how much profit Sprint Bioscience AB makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Sprint Bioscience AB to the Biotechnology industry mean.
  • An Operating Margin of -46.1% means the company generated kr-0.46  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Sprint Bioscience AB:

  • The MRQ is -46.1%. The company is operating very inefficient. -2
  • The TTM is -7,145.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-46.1%TTM-7,145.9%+7,099.8%
TTM-7,145.9%YOY-127,492.7%+120,346.8%
TTM-7,145.9%5Y-28,959.8%+21,813.9%
5Y-28,959.8%10Y-14,860.0%-14,099.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-46.1%-298.0%+251.9%
TTM-7,145.9%-238.5%-6,907.4%
YOY-127,492.7%-288.4%-127,204.3%
5Y-28,959.8%-486.2%-28,473.6%
10Y-14,860.0%-628.4%-14,231.6%
1.2.2. Operating Ratio

Measures how efficient Sprint Bioscience AB is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.77 means that the operating costs are kr2.77 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Sprint Bioscience AB:

  • The MRQ is 2.767. The company is inefficient in keeping operating costs low. -1
  • The TTM is 73.201. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.767TTM73.201-70.434
TTM73.201YOY1,475.231-1,402.029
TTM73.2015Y330.792-257.591
5Y330.79210Y169.516+161.276
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7673.235-0.468
TTM73.2013.310+69.891
YOY1,475.2313.838+1,471.393
5Y330.7925.679+325.113
10Y169.5167.823+161.693

1.3. Liquidity of Sprint Bioscience AB.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Sprint Bioscience AB is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.67 means the company has kr1.67 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Sprint Bioscience AB:

  • The MRQ is 1.672. The company is able to pay all its short-term debts. +1
  • The TTM is 1.627. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.672TTM1.627+0.045
TTM1.627YOY4.982-3.355
TTM1.6275Y3.072-1.444
5Y3.07210Y2.238+0.833
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6723.863-2.191
TTM1.6274.169-2.542
YOY4.9825.337-0.355
5Y3.0726.122-3.050
10Y2.2386.434-4.196
1.3.2. Quick Ratio

Measures if Sprint Bioscience AB is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Sprint Bioscience AB to the Biotechnology industry mean.
  • A Quick Ratio of 1.67 means the company can pay off kr1.67 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Sprint Bioscience AB:

  • The MRQ is 1.672. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.627. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.672TTM1.627+0.045
TTM1.627YOY4.982-3.355
TTM1.6275Y2.868-1.241
5Y2.86810Y2.003+0.866
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6723.504-1.832
TTM1.6273.991-2.364
YOY4.9825.371-0.389
5Y2.8686.088-3.220
10Y2.0036.395-4.392

1.4. Solvency of Sprint Bioscience AB.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Sprint Bioscience AB assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Sprint Bioscience AB to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.55 means that Sprint Bioscience AB assets are financed with 55.5% credit (debt) and the remaining percentage (100% - 55.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Sprint Bioscience AB:

  • The MRQ is 0.555. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.598. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.555TTM0.598-0.043
TTM0.598YOY0.208+0.390
TTM0.5985Y0.424+0.174
5Y0.42410Y0.393+0.031
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5550.339+0.216
TTM0.5980.337+0.261
YOY0.2080.271-0.063
5Y0.4240.368+0.056
10Y0.3930.388+0.005
1.4.2. Debt to Equity Ratio

Measures if Sprint Bioscience AB is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Sprint Bioscience AB to the Biotechnology industry mean.
  • A Debt to Equity ratio of 124.6% means that company has kr1.25 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Sprint Bioscience AB:

  • The MRQ is 1.246. The company is able to pay all its debts with equity. +1
  • The TTM is 1.953. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.246TTM1.953-0.707
TTM1.953YOY0.269+1.684
TTM1.9535Y1.555+0.399
5Y1.55510Y1.225+0.330
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2460.392+0.854
TTM1.9530.403+1.550
YOY0.2690.335-0.066
5Y1.5550.427+1.128
10Y1.2250.461+0.764

2. Market Valuation of Sprint Bioscience AB

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Sprint Bioscience AB generates.

  • Above 15 is considered overpriced but always compare Sprint Bioscience AB to the Biotechnology industry mean.
  • A PE ratio of -6.01 means the investor is paying kr-6.01 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Sprint Bioscience AB:

  • The EOD is -4.659. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.005. Based on the earnings, the company is expensive. -2
  • The TTM is -1.610. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.659MRQ-6.005+1.346
MRQ-6.005TTM-1.610-4.395
TTM-1.610YOY-2.446+0.836
TTM-1.6105Y-5.819+4.209
5Y-5.81910Y33.810-39.629
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.659-2.300-2.359
MRQ-6.005-2.656-3.349
TTM-1.610-2.718+1.108
YOY-2.446-4.145+1.699
5Y-5.819-6.258+0.439
10Y33.810-6.315+40.125
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Sprint Bioscience AB:

  • The EOD is -4.573. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.894. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.569. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.573MRQ-5.894+1.322
MRQ-5.894TTM-2.569-3.325
TTM-2.569YOY-2.572+0.003
TTM-2.5695Y-2.308-0.261
5Y-2.30810Y-22.709+20.401
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.573-2.974-1.599
MRQ-5.894-3.306-2.588
TTM-2.569-3.508+0.939
YOY-2.572-5.613+3.041
5Y-2.308-8.378+6.070
10Y-22.709-8.873-13.836
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Sprint Bioscience AB is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.36 means the investor is paying kr4.36 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Sprint Bioscience AB:

  • The EOD is 3.384. Based on the equity, the company is fair priced.
  • The MRQ is 4.362. Based on the equity, the company is fair priced.
  • The TTM is 5.119. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD3.384MRQ4.362-0.978
MRQ4.362TTM5.119-0.757
TTM5.119YOY3.660+1.459
TTM5.1195Y27.474-22.355
5Y27.47410Y63.943-36.470
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.3841.914+1.470
MRQ4.3622.116+2.246
TTM5.1192.097+3.022
YOY3.6602.881+0.779
5Y27.4743.550+23.924
10Y63.9433.936+60.007
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Sprint Bioscience AB compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.072-0.001-98%-0.118+63%-0.007-91%0.009-927%
Book Value Per Share--0.3980.289+38%0.529-25%0.448-11%0.406-2%
Current Ratio--1.6721.627+3%4.982-66%3.072-46%2.238-25%
Debt To Asset Ratio--0.5550.598-7%0.208+167%0.424+31%0.393+41%
Debt To Equity Ratio--1.2461.953-36%0.269+363%1.555-20%1.225+2%
Dividend Per Share----0%-0%-0%-0%
Eps---0.072-0.002-98%-0.215+198%-0.106+47%-0.073+1%
Free Cash Flow Per Share---0.0740.073-201%-0.211+187%-0.100+36%-0.080+9%
Free Cash Flow To Equity Per Share---0.0740.073-200%-0.083+13%0.094-179%0.052-242%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---0.188--------
Intrinsic Value_10Y_min---3.524--------
Intrinsic Value_1Y_max---0.277--------
Intrinsic Value_1Y_min---0.377--------
Intrinsic Value_3Y_max---0.635--------
Intrinsic Value_3Y_min---1.119--------
Intrinsic Value_5Y_max---0.757--------
Intrinsic Value_5Y_min---1.840--------
Market Cap93977849.216-29%121137866.56084813961.616+43%149292820.272-19%448040941.480-73%1049555307.169-88%
Net Profit Margin---0.464-71.459+15314%-1237.941+266930%-283.482+61048%-145.532+31292%
Operating Margin---0.461-71.459+15406%-1274.927+276554%-289.598+62741%-148.600+32145%
Operating Ratio--2.76773.201-96%1475.231-100%330.792-99%169.516-98%
Pb Ratio3.384-29%4.3625.119-15%3.660+19%27.474-84%63.943-93%
Pe Ratio-4.659+22%-6.005-1.610-73%-2.446-59%-5.819-3%33.810-118%
Price Per Share1.346-29%1.7351.215+43%2.138-19%6.380-73%15.014-88%
Price To Free Cash Flow Ratio-4.573+22%-5.894-2.569-56%-2.572-56%-2.308-61%-22.709+285%
Price To Total Gains Ratio-18.632+22%-24.016-6.441-73%-15.268-36%-2.057-91%212.204-111%
Quick Ratio--1.6721.627+3%4.982-66%2.868-42%2.003-16%
Return On Assets---0.081-0.125+55%-0.341+322%-0.267+230%-0.189+134%
Return On Equity---0.182-0.719+296%-0.438+141%-0.852+369%-0.537+196%
Total Gains Per Share---0.072-0.001-98%-0.118+63%-0.007-91%0.009-927%
Usd Book Value--2552430.6001853967.625+38%3397198.375-25%2917195.485-13%2627704.546-3%
Usd Book Value Change Per Share---0.0070.000-98%-0.011+63%-0.001-91%0.001-927%
Usd Book Value Per Share--0.0370.027+38%0.049-25%0.041-11%0.037-2%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.0070.000-98%-0.020+198%-0.010+47%-0.007+1%
Usd Free Cash Flow---472182.200469080.575-201%-1356765.650+187%-651515.860+38%-518226.407+10%
Usd Free Cash Flow Per Share---0.0070.007-201%-0.019+187%-0.009+36%-0.007+9%
Usd Free Cash Flow To Equity Per Share---0.0070.007-200%-0.008+13%0.009-179%0.005-242%
Usd Market Cap8636564.343-29%11132569.9377794403.073+43%13720010.183-19%41174962.522-73%96454132.729-88%
Usd Price Per Share0.124-29%0.1590.112+43%0.197-19%0.586-73%1.380-88%
Usd Profit---463451.700-9626.525-98%-1366897.625+195%-686097.830+48%-470102.668+1%
Usd Revenue--999688.2001159892.875-14%1883.950+52963%625416.260+60%507121.875+97%
Usd Total Gains Per Share---0.0070.000-98%-0.011+63%-0.001-91%0.001-927%
 EOD+3 -5MRQTTM+18 -15YOY+21 -125Y+17 -1610Y+15 -18

3.2. Fundamental Score

Let's check the fundamental score of Sprint Bioscience AB based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.659
Price to Book Ratio (EOD)Between0-13.384
Net Profit Margin (MRQ)Greater than0-0.464
Operating Margin (MRQ)Greater than0-0.461
Quick Ratio (MRQ)Greater than11.672
Current Ratio (MRQ)Greater than11.672
Debt to Asset Ratio (MRQ)Less than10.555
Debt to Equity Ratio (MRQ)Less than11.246
Return on Equity (MRQ)Greater than0.15-0.182
Return on Assets (MRQ)Greater than0.05-0.081
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Sprint Bioscience AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.892
Ma 20Greater thanMa 501.221
Ma 50Greater thanMa 1001.083
Ma 100Greater thanMa 2001.216
OpenGreater thanClose1.332
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Total Other Income Expense Net 189-168218810969178-208-30



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in SEK. All numbers in thousands.

Summary
Total Assets62,377
Total Liabilities34,603
Total Stockholder Equity27,774
 As reported
Total Liabilities 34,603
Total Stockholder Equity+ 27,774
Total Assets = 62,377

Assets

Total Assets62,377
Total Current Assets57,872
Long-term Assets4,505
Total Current Assets
Cash And Cash Equivalents 49,934
Net Receivables 7,938
Inventory -7,136
Other Current Assets 7,136
Total Current Assets  (as reported)57,872
Total Current Assets  (calculated)57,872
+/-0
Long-term Assets
Property Plant Equipment 4,378
Long-term Assets Other 77
Long-term Assets  (as reported)4,505
Long-term Assets  (calculated)4,455
+/- 50

Liabilities & Shareholders' Equity

Total Current Liabilities34,603
Long-term Liabilities0
Total Stockholder Equity27,774
Total Current Liabilities
Short-term Debt -12,318
Accounts payable 5,705
Other Current Liabilities 28,898
Total Current Liabilities  (as reported)34,603
Total Current Liabilities  (calculated)22,285
+/- 12,318
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock6,982
Retained Earnings -253,103
Other Stockholders Equity 273,895
Total Stockholder Equity (as reported)27,774
Total Stockholder Equity (calculated)27,774
+/-0
Other
Capital Stock6,982
Cash and Short Term Investments 49,934
Common Stock Shares Outstanding 69,820
Current Deferred Revenue12,318
Liabilities and Stockholders Equity 62,377
Net Debt -49,934
Net Invested Capital 27,774
Net Working Capital 23,269
Property Plant and Equipment Gross 9,664



Balance Sheet

Currency in SEK. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-30
> Total Assets 
0
7,472
0
11,667
8,810
25,147
21,767
16,461
35,696
30,633
42,645
32,063
53,723
49,522
42,268
39,438
44,478
35,485
77,682
66,453
55,997
59,290
62,451
66,814
60,024
19,244
21,063
56,624
45,823
33,399
17,962
19,808
95,403
79,137
63,913
47,702
34,351
37,422
34,130
23,004
63,768
62,377
62,37763,76823,00434,13037,42234,35147,70263,91379,13795,40319,80817,96233,39945,82356,62421,06319,24460,02466,81462,45159,29055,99766,45377,68235,48544,47839,43842,26849,52253,72332,06342,64530,63335,69616,46121,76725,1478,81011,66707,4720
   > Total Current Assets 
0
907
0
3,867
452
15,095
10,012
3,731
21,868
14,600
24,876
14,440
33,781
26,915
16,967
11,396
4,738
4,879
7,208
30,264
16,723
18,312
21,519
26,068
19,453
17,379
19,392
11,797
44,530
32,273
16,151
7,884
92,027
75,937
60,885
44,838
31,649
34,882
31,749
20,758
61,617
57,872
57,87261,61720,75831,74934,88231,64944,83860,88575,93792,0277,88416,15132,27344,53011,79719,39217,37919,45326,06821,51918,31216,72330,2647,2084,8794,73811,39616,96726,91533,78114,44024,87614,60021,8683,73110,01215,0954523,86709070
       Cash And Cash Equivalents 
0
603
0
3,512
2
13,976
9,084
2,762
15,384
7,627
18,985
12,481
31,557
23,607
14,226
6,617
1,913
1,479
4,358
27,160
12,812
14,690
13,820
4,419
11,156
8,380
10,162
1,452
35,416
27,075
13,294
4,656
85,708
70,644
56,981
41,441
26,729
29,493
27,243
15,503
55,072
49,934
49,93455,07215,50327,24329,49326,72941,44156,98170,64485,7084,65613,29427,07535,4161,45210,1628,38011,1564,41913,82014,69012,81227,1604,3581,4791,9136,61714,22623,60731,55712,48118,9857,62715,3842,7629,08413,97623,51206030
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,297
6,824
9,230
10,345
9,114
3,284
2,857
3,228
6,319
5,293
3,904
3,397
4,920
5,389
4,506
5,255
6,545
7,938
7,9386,5455,2554,5065,3894,9203,3973,9045,2936,3193,2282,8573,2849,11410,3459,2306,8248,297000000000000000000000000
       Other Current Assets 
0
205
0
355
450
1,118
928
969
2,753
6,972
5,891
1,959
-1
3,308
-1
-1
2,825
3,400
2,850
3,104
3,911
3,622
7,699
21,649
8,297
8,999
9,230
10,345
9,114
1
2,857
3,228
6,319
5,293
3,904
3,397
4,920
1
4,506
5,255
6,545
7,136
7,1366,5455,2554,50614,9203,3973,9045,2936,3193,2282,85719,11410,3459,2308,9998,29721,6497,6993,6223,9113,1042,8503,4002,825-1-13,308-11,9595,8916,9722,7539699281,11845035502050
   > Long-term Assets 
0
6,565
0
7,800
8,358
10,052
11,755
12,730
13,828
16,034
17,769
17,623
19,942
22,607
25,300
28,043
39,741
30,606
70,474
36,190
39,274
40,978
40,932
40,746
40,571
1,865
1,671
44,827
1,292
1,126
1,811
11,924
3,376
3,200
3,028
2,864
2,702
2,540
2,381
2,246
2,151
4,505
4,5052,1512,2462,3812,5402,7022,8643,0283,2003,37611,9241,8111,1261,29244,8271,6711,86540,57140,74640,93240,97839,27436,19070,47430,60639,74128,04325,30022,60719,94217,62317,76916,03413,82812,73011,75510,0528,3587,80006,5650
       Property Plant Equipment 
0
576
0
582
590
547
572
528
696
1,152
1,248
1,634
1,859
1,872
1,736
2,503
2,330
1,512
1,435
2,214
2,072
2,207
2,116
1,930
1,755
1,569
1,386
1,203
1,028
872
1,568
1,692
3,154
2,989
2,827
2,674
2,522
2,371
2,222
2,098
2,014
4,378
4,3782,0142,0982,2222,3712,5222,6742,8272,9893,1541,6921,5688721,0281,2031,3861,5691,7551,9302,1162,2072,0722,2141,4351,5122,3302,5031,7361,8721,8591,6341,2481,15269652857254759058205760
       Intangible Assets 
0
0
0
0
7,768
9,506
11,183
12,202
13,132
14,882
16,521
15,989
18,083
20,734
23,564
25,540
27,098
29,094
31,165
33,976
37,202
38,771
38,771
38,771
38,771
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000038,77138,77138,77138,77137,20233,97631,16529,09427,09825,54023,56420,73418,08315,98916,52114,88213,13212,20211,1839,5067,7680000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
-1
-1
0
0
-1
0
0
0
38,816
38,816
246
235
43,574
1
204
193
10,182
172
161
151
140
130
119
109
98
87
0
0879810911913014015116117210,182193204143,57423524638,81638,816000-100-1-1100000000000000
> Total Liabilities 
0
4,109
0
4,643
4,488
4,827
5,286
5,020
26,863
25,813
22,165
7,493
28,634
21,027
12,696
8,890
9,140
7,396
9,883
9,448
7,969
22,047
7,984
7,856
8,253
8,227
19,804
23,659
22,156
24,255
22,211
8,451
9,910
8,683
7,664
9,360
9,265
9,234
18,226
18,805
30,950
34,603
34,60330,95018,80518,2269,2349,2659,3607,6648,6839,9108,45122,21124,25522,15623,65919,8048,2278,2537,8567,98422,0477,9699,4489,8837,3969,1408,89012,69621,02728,6347,49322,16525,81326,8635,0205,2864,8274,4884,64304,1090
   > Total Current Liabilities 
0
1,804
0
2,338
2,110
3,288
3,747
3,481
25,325
25,044
21,395
6,724
27,865
21,027
12,695
8,890
9,140
7,396
9,883
9,448
7,969
22,046
7,985
7,856
8,253
8,227
19,804
23,659
22,155
24,255
22,211
8,451
9,910
8,683
7,664
9,360
9,265
9,234
18,226
18,805
30,950
34,603
34,60330,95018,80518,2269,2349,2659,3607,6648,6839,9108,45122,21124,25522,15523,65919,8048,2278,2537,8567,98522,0467,9699,4489,8837,3969,1408,89012,69521,02727,8656,72421,39525,04425,3253,4813,7473,2882,1102,33801,8040
       Short-term Debt 
0
195
0
195
195
769
577
385
192
769
577
385
186
769
577
385
192
0
0
0
0
12,000
0
0
0
0
0
0
0
10,000
0
0
0
0
0
0
0
0
0
0
0
-12,318
-12,3180000000000010,000000000012,000000019238557776918638557776919238557776919519501950
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,000
0
0
0
0
0
0
0
0
0
0
0
0
00000000000010,00000000000000000000000000000000
       Accounts payable 
0
619
0
713
660
888
1,610
1,030
1,557
2,583
2,680
2,328
1,601
3,621
1,781
4,084
4,793
3,394
5,704
4,760
3,603
4,710
3,077
2,301
3,402
2,594
3,239
2,130
2,430
3,397
2,435
3,633
3,954
2,923
2,334
2,163
4,219
3,725
2,335
2,430
5,109
5,705
5,7055,1092,4302,3353,7254,2192,1632,3342,9233,9543,6332,4353,3972,4302,1303,2392,5943,4022,3013,0774,7103,6034,7605,7043,3944,7934,0841,7813,6211,6012,3282,6802,5831,5571,0301,61088866071306190
       Other Current Liabilities 
0
990
0
1,430
1,255
346
1,560
2,066
23,576
447
18,138
4,011
26,078
0
10,337
4,421
4,155
4,002
4,179
4,688
4,366
670
4,908
5,555
4,851
5,633
16,565
21,529
19,725
1,748
19,776
4,818
5,956
5,760
5,330
7,197
5,046
5,509
15,891
16,375
25,841
28,898
28,89825,84116,37515,8915,5095,0467,1975,3305,7605,9564,81819,7761,74819,72521,52916,5655,6334,8515,5554,9086704,3664,6884,1794,0024,1554,42110,337026,0784,01118,13844723,5762,0661,5603461,2551,43009900
   > Long-term Liabilities 
0
2,305
0
2,305
2,378
1,538
1,539
1,539
1,538
769
770
769
769
0
1
0
0
0
0
0
0
1
-1
0
0
0
0
0
1
0
0
0
0
2,923
2,334
2,163
4,219
0
2,335
0
0
0
0002,33504,2192,1632,3342,9230000100000-11000000107697697707691,5381,5391,5391,5382,3782,30502,3050
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000010000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
38,771
38,771
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000038,77138,77100000000000000000000000
> Total Stockholder Equity
0
3,363
0
7,024
4,322
20,320
16,481
11,441
8,833
4,820
20,480
24,570
25,089
28,495
29,572
30,548
35,338
28,089
67,799
57,005
48,028
37,243
54,467
58,958
51,771
11,017
1,259
32,965
23,667
9,144
-4,249
11,357
85,493
70,454
56,249
38,342
25,086
28,188
15,904
4,199
32,818
27,774
27,77432,8184,19915,90428,18825,08638,34256,24970,45485,49311,357-4,2499,14423,66732,9651,25911,01751,77158,95854,46737,24348,02857,00567,79928,08935,33830,54829,57228,49525,08924,57020,4804,8208,83311,44116,48120,3204,3227,02403,3630
   Common Stock
0
195
0
195
503
654
654
654
654
654
654
706
706
706
706
706
706
757
757
1,010
1,010
1,010
1,010
1,010
1,163
1,234
1,234
1,234
2,121
2,121
2,125
2,531
3,984
3,984
3,984
3,984
3,984
6,980
6,980
6,982
6,982
6,982
6,9826,9826,9826,9806,9803,9843,9843,9843,9843,9842,5312,1252,1212,1211,2341,2341,2341,1631,0101,0101,0101,0101,01075775770670670670670670665465465465465465450319501950
   Retained Earnings Total Equity000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
134,403
134,410
178,634
174,435
174,435
174,733
203,848
258,965
258,965
258,965
258,965
258,965
273,873
273,873
273,895
273,897
0
0273,897273,895273,873273,873258,965258,965258,965258,965258,965203,848174,733174,435174,435178,634134,410134,4030000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
12,178
0
20,880
20,571
40,141
40,141
40,141
40,141
40,141
60,265
59,681
61,774
67,960
70,790
72,765
84,636
86,526
121,184
122,595
125,752
127,320
152,364
152,364
152,211
134,403
134,410
178,634
174,435
174,435
174,733
203,848
258,965
258,965
258,965
258,965
258,965
273,873
273,873
273,895
273,897
273,895
273,895273,897273,895273,873273,873258,965258,965258,965258,965258,965203,848174,733174,435174,435178,634134,410134,403152,211152,364152,364127,320125,752122,595121,18486,52684,63672,76570,79067,96061,77459,68160,26540,14140,14140,14140,14140,14120,57120,880012,1780



Balance Sheet

Currency in SEK. All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue50,485
Cost of Revenue-54,217
Gross Profit-3,732-3,732
 
Operating Income (+$)
Gross Profit-3,732
Operating Expense-44,314
Operating Income-3,732-48,046
 
Operating Expense (+$)
Research Development0
Selling General Administrative0
Selling And Marketing Expenses0
Operating Expense44,3140
 
Net Interest Income (+$)
Interest Income794
Interest Expense-387
Other Finance Cost-387
Net Interest Income794
 
Pretax Income (+$)
Operating Income-3,732
Net Interest Income794
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-438-7,026
EBIT - interestExpense = -4,119
-438
-51
Interest Expense387
Earnings Before Interest and Taxes (EBIT)-3,732-51
Earnings Before Interest and Taxes (EBITDA)-3,285
 
After tax Income (+$)
Income Before Tax-438
Tax Provision-0
Net Income From Continuing Ops-438-438
Net Income-438
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses54,217
Total Other Income/Expenses Net3,294-794
 

Technical Analysis of Sprint Bioscience AB
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Sprint Bioscience AB. The general trend of Sprint Bioscience AB is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Sprint Bioscience AB's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Sprint Bioscience AB.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.59 < 1.92 < 2.

The bearish price targets are: 0.974 > 0.832 > 0.83.

Tweet this
Sprint Bioscience AB Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Sprint Bioscience AB. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Sprint Bioscience AB Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Sprint Bioscience AB. The current macd is 0.0751474.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Sprint Bioscience AB price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Sprint Bioscience AB. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Sprint Bioscience AB price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Sprint Bioscience AB Daily Moving Average Convergence/Divergence (MACD) ChartSprint Bioscience AB Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Sprint Bioscience AB. The current adx is 47.60.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Sprint Bioscience AB shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Sprint Bioscience AB Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Sprint Bioscience AB. The current sar is 1.11697576.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Sprint Bioscience AB Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Sprint Bioscience AB. The current rsi is 58.89. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Sprint Bioscience AB Daily Relative Strength Index (RSI) ChartSprint Bioscience AB Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Sprint Bioscience AB. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Sprint Bioscience AB price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Sprint Bioscience AB Daily Stochastic Oscillator ChartSprint Bioscience AB Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Sprint Bioscience AB. The current cci is 75.28.

Sprint Bioscience AB Daily Commodity Channel Index (CCI) ChartSprint Bioscience AB Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Sprint Bioscience AB. The current cmo is 18.01.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Sprint Bioscience AB Daily Chande Momentum Oscillator (CMO) ChartSprint Bioscience AB Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Sprint Bioscience AB. The current willr is -43.72759857.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Sprint Bioscience AB is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Sprint Bioscience AB Daily Williams %R ChartSprint Bioscience AB Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Sprint Bioscience AB.

Sprint Bioscience AB Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Sprint Bioscience AB. The current atr is 0.17795748.

Sprint Bioscience AB Daily Average True Range (ATR) ChartSprint Bioscience AB Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Sprint Bioscience AB. The current obv is 4,533,153.

Sprint Bioscience AB Daily On-Balance Volume (OBV) ChartSprint Bioscience AB Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Sprint Bioscience AB. The current mfi is 68.74.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Sprint Bioscience AB Daily Money Flow Index (MFI) ChartSprint Bioscience AB Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Sprint Bioscience AB.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-22RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-22MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-24STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Sprint Bioscience AB Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Sprint Bioscience AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.892
Ma 20Greater thanMa 501.221
Ma 50Greater thanMa 1001.083
Ma 100Greater thanMa 2001.216
OpenGreater thanClose1.332
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Sprint Bioscience AB with someone you think should read this too:
  • Are you bullish or bearish on Sprint Bioscience AB? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Sprint Bioscience AB? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Sprint Bioscience AB

I send you an email if I find something interesting about Sprint Bioscience AB.


Comments

How you think about this?

Leave a comment

Stay informed about Sprint Bioscience AB.

Receive notifications about Sprint Bioscience AB in your mailbox!